PMV Pharma to present updated Phase 1 PC14586 data at AACR-NCI-EORTC; KOL webinar planned

PMV Pharmaceuticals, Inc.

Updated Phase 1 data cutoff Sep 5, 2023; abstract with May 1 cutoff published.
Poster session October 12, 2023 12:30-4:00 PM ET at AACR-NCI-EORTC conference.
PC14586 targets p53 Y220C mutation in advanced solid tumors; PYNNACLE study ongoing.
KOL webinar October 12 at 4:00 PM ET with regulatory update included.
Data also discussed in Chemistry in Cancer Research Town Hall and Concurrent Session 8.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.